Management of cancer pain: 1. wider implications of orthodox analgesics

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 49-58

  Lee, Susannah K ^a   Dawson, Jill ^b   Lee, Jack A ^c   Osman, Gizem ^d   Levitin, Maria O ^e   Guzel, Refika Mine ^e   Djamgoz, Mustafa Ba ^e,f  

^a POMONA COLLEGE   (United States)

^b Healthcare Consulting   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f CYPRUS INTERNATIONAL UNIVERSITY   (Turkey)

Author keywords

Cannabinoids; GABA mimetics; GABA ergic drugs; Ion channels; NSAIDs; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CANNABINOID; CAPSAICIN; CODEINE; DENOSUMAB; DIAZEPAM; DRONABINOL; FENTANYL; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; METHADONE; MORPHINE; NABIXIMOLS; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PECTIN; PLACEBO; PREGABALIN; ZOLEDRONIC ACID;

BREAKTHROUGH PAIN; CANCER GROWTH; CANCER PAIN; CANCER RISK; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HUMAN; HYPERALGESIA; IN VITRO STUDY; LOW DRUG DOSE; NEUROPATHIC PAIN; POSTOPERATIVE PAIN; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN PAIN; TUMOR VASCULARIZATION;

EID: 84892166422     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S42187     Document Type: Review

References (85)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a populationbased study. Lancet Oncol. 2012;13(8):790-801.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-1907.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
4. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2011;4:448-456.
5. Williams AC de C, Gessler S. Empathy in cancer pain. In: Pace JA, Bell RF, Kalso EA, Soyannwo OA, editors. Cancer Pain: From Molecules to Suffering. Washington, DC: International Association for the Study of Pain; 2010: chapter 16.
6. Ripamonti C, Longo M. Cancer pain syndromes and pharmacotherapy of cancer pain. Arch Oncol. 2004;12(3):168-170.
7. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61(3):157-182.
8. Sabiston CM, Brunet J, Burke S. Pain, movement, and mind: does physical activity mediate the relationship between pain and mental health among survivors of breast cancer? Clin J Pain. 2012;28(6):489-495.
9. Anand U. Mechanisms and management of cancer pain. In: Alison MR, editor. The Cancer Handbook. 2nd ed. Chichester, UK: John Wiley & Sons; 2007.
10. Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19(2):92-101.
11. Greenspan JD, Craft RM, LeResche L, et-alet al/et-al; The Consensus Working Group of the Sex, Gender, and Pain SIG of the IASP. Studying sex and gender differences in pain and analgesia: a consensus report. Pain. 2007;132(Suppl 1):S26-S45.
12. Fallon M. When morphine does not work. Support Care Cancer. 2008;16:771-775.
13. Portenoy RK, Ahmed E, Keilson YY. Cancer pain management: use of acetaminophen and nonsteroidal anti-inflammatory drugs. UpToDate. May 1, 2012. 18.
14. Costa E, Guidotti A, Mao CC, Suria A. New concepts on the mechanism of action of benzodiazepines. Life Sci. 1975;17:167-185.
15. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
16. Hendrich J, Van Minh AT, Heblich F, et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci U S A. 2008;105:3628-3633.
17. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol. 2007;20:456-472.
18. Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioidtreated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5): 438-449.
19. Lee MC, Ploner M, Wiech K, et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain. 2013;154(1): 124-134.
20. National Institute for Health and Clinical Excellence. Opioids in Palliative Care: Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults. Clinical Guideline 140. Available from: http://publications.nice.org.uk/opioids-in-palliative-care-safe-andeffective-prescribing-of-strong-opioids-for-pain-in-palliative-cg140. Accessed August 23, 2013
21. Cherny N, et al. (2001). Strategies to manage the adverse effects of oral morphine: an evidence based report. Journal of Clinical Oncology, 19, 2542-2554. Cited in Uma Anand. Mechanisms and Management of Cancer Pain. The Cancer Handbook, 2nd Edition. Edited by Malcolm R Alison. 2007 John Wiley & Sons, Ltd.
22. Salminen EK, Silvoniemi M, Syrjänen K, Kaasa S, Kloke M, Klepstad P. Opioids in pain management of mesothelioma and lung cancer patients. Acta Oncol. 2013;52(1):30-37.
23. Wallace E, Ridley J, Bryson J, Mak E, Zimmermann C. Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. J Palliat Med. 2013;16(3):305-309.
24. Bulloch MN, Hutchison AM. Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain. Expert Rev Clin Pharmacol. 2013;6(1):9-22.
25. Escobar Y, Mañas A, Juliá J, et al. Optimal management of breakthrough cancer pain (BCP). Clin Transl Oncol. Epub December 21, 2012.
26. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. February 1, 2013. pii: S0885-3924(12)00815-00819.
27. Zhu YL, Song GH, Liu DQ, et al. Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 Chinese cancer patients. Chin J Cancer Res. 2011;23(4):317-322.
28. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013;119(4):832-838.
29. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9:571-591.
30. Vargas-Shaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514-517.
31. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Review: Cyclooxygenase-2 (COX-2) independent anticarcinogenic effects of selective COX-2 inhibitors. J Nat Cancer Inst. 2006;98(11):736-747.
32. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res. 2013;191:67-93.
33. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518-527.
34. Rothwell PM, Wilson M, Price JF, Belch JFF, Meades TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-1601.
35. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet Oncol. 2012;379:1602-1612.
36. Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and urologic cancer risk: an update. Nat Rev Urol. 2012;9(2):102-110.
37. Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the Prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol. 2011;29(17):2424-2431.
38. Choueiri TK, Je Y, Cho E. Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer. Epub February 7, 2013.
39. Roberts SS, Mori M, Pattee P, et al. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol. 2004;22:4127-4134.
40. Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor P subunit. Cancer Res. 2007;67:9704-9712.
41. Azuma H, Inamoto T, Sakamoto T, et al. Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism. Cancer Res. 2003;63:8090-8096.
42. Takehara A, Hosokawa M, Eguchi H, et al. γ-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor π subunit. Cancer Res. 2007;67:9704-9712.
43. Ortega A. A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol Sci. 2003;24:151-154.
44. Johnson SK, Dennis RA, Barone GW, Lamps LW, Haun RS. Differential expression of insulin-like growth factor binding protein-5 in pancreatic adenocarcinomas: identification using DNA microarray. Mol Carcinog. 2006;45(11):814-827.
45. Maemura K, Shiraishi N, Sakagami K, et al. Proliferative effects of γ-aminobutyric acid on the gastric cancer cell line are associated with extracellular signal-regulated kinase 1/2 activation. J Gastroenterol Hepatol. 2009;24;688-696.
46. Zafrakas M, Chorovicer M, Klaman I, et al. Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer. 2006;118(6):1453-1459.
47. Al-Wadei HA, Al-Wadei MH, Ullah MF, Schuller HM. Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. PLoS One. 2012;7(8):e43376.
48. Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012;53 Suppl 8:12-25.
49. Miyawaki I, Moriyasu M, Funabashi H, Yasuba M, Matsuoka N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol Lett. 2003;145:291-301.
50. Pottegård A, Friis S, Andersen M, Hallas J. Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2013;75(5):1356-1364.
51. Xie J, Li Y, Huang Y, et al. Anesthetic pentobarbital inhibits proliferation and migration of malignant glioma cells. Cancer Lett. 2009;282(1): 35-42.
52. Dethloff L, Barr B, Bestervelt L, Bulera S, Sigler R, LaGattuta M. Gabapentin-induced mitogenic activity in rat pancreatic acinar cells. Toxicol Sci. 2000;55:52-59.
53. Henle F, Leemhuis J, Fischer C, et al. Gabapentin-lactam induces dendritic filopodia and motility in cultured hippocampal neurons. J Pharmacol Exp Ther. 2006;319:181-191.
54. Sigler RE, Gough AW, De La Iglesia FA. Pancreatic acinar cell neoplasia in male Wistar rats following 2 years of gabapentin exposure. Toxicology. 1995;98(1-3):73-82.
55. Friedman GD, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control. 2009;20(10):1821-1835.
56. Criswell KA, Cook JC, Morse D, et al. Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation. Toxicol Sci. 201;128: 42-56.
57. Pegg D, Bleavins M, Herman J, et al. Hemangiosarcoma in mice administered pregabalin: analysis of genotoxicity, tumor incidence, and tumor genetics. Toxicol Sci. 2012;128:9-21.
58. Criswell KA, Wojcinski Z, Pegg D, et al. Key components of the mode of action for hemangiosarcoma induction in pregabalin-treated mice: evidence of increased bicarbonate, dysregulated erythropoiesis, macrophage activation, and increased angiogenic growth factors in mice but not in rats. Toxicol Sci. 2012;128:22-41.
59. Criswell KA, Cook JC, Wojcinski Z, et al. Mode of action associated with development of hemangiosarcoma in mice given pregabalin and assessment of human relevance. Toxicol Sci. 2012;128:57-71.
60. Carriot F, Sasco AJ. Cannabis and cancer. Rev Epidemiol Sante Publique. 2000;48:473-483.
61. Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, et al. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res. 2013;28(1):92-107.
62. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62:4491-4498.
63. Qin Y, Chen J, Li L, et al. Exogenous morphine inhibits human gastric cancer MGC-803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev. 2012;13(4):1377-1382.
64. Gong L, Dong C, Ouyang W, Qin Q. Regulatory T cells: a possible promising approach to cancer recurrence induced by morphine. Med Hypotheses. 2013;80(3):308-310.
65. Qin Y, Li L, Chen J, et al. Fentanyl inhibits progression of human gastric cancer MGC-803 cells by NF-kappaB downregulation and PTEN upregulation in vitro. Oncol Res. 2012;20(2-3):61-69.
66. Shakeri R, Malekzadeh R, Etemadi A, et al. Opium; an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455-461.
67. Gach K, Wyrebska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(3):221-230.
68. Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev. 2011;30:225-238.
69. Wood JN. Ion channels in analgesia research. Handb Exp Pharmacol. 2007;(177):329-358.
70. Vink S, Alewood PF. Targeting voltage-gated calcium channels: developments in peptide and small molecule inhibitors for the treatment of neuropathic pain. Br J Pharmacol. 2012;167:970-989.
71. Liu M, Wood JN. The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. Pain Med. 2011;12(Suppl 3): S93-S99.
72. Panner A, Wurster RD. T-type calcium channels and tumor proliferation. Cell Calcium. 2006;40:253-259.
73. Fraser SP, Diss JK, Chioni AM, et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 2005;11:5381-5389.
74. Onkal R, Djamgoz MB. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. Eur J Pharmacol. 2009;625:206-219.
75. Premkumar LS, Abooj M. TRP channels and analgesia. Life Sci. 2013;92(8-9):415-424.
76. Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A. TRP channels: diagnostic markers and therapeutic targets for breast cancer? Trends Mol Med. 2013;19(2):117-124.
77. Magni G, Ceruti S. P2Y purinergic receptors: new targets for analgesic and antimigraine drugs. Biochem Pharmacol. 2013;85(4):466-477.
78. North RA, Jarvis MF. P2X Receptors as drug targets. Mol Pharmacol. 2013;83(4):759-769.
79. Kłopocka W, Korczyński J, Pomorski P. Cytoskeleton and nucleotide signaling in glioma C6 cells. Adv Exp Med Biol. 2013;986: 103-119.
80. Braganhol E, Wink MR, Lenz G, Battastini AM. Purinergic signaling in glioma progression. Adv Exp Med Biol. 2013;986:81-102.
81. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22:349-359.
82. Brackenbury WJ, Djamgoz MB. Nerve growth factor enhances voltage-gated Na+ channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line. J Cell Physiol. 2007;210:602-608.
83. Vigneault L, Turgeon AF, Côté D, et al. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011;58(1):22-37.
84. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth. 2010;105(2): 106-115.
85. Borsook D. A future without chronic pain: neuroscience and clinical research. Cerebrum. May 2012;2012:7.